AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 205687 — intervention group
Group type: COMPARATOR
Intervention: Control plasma (lacking varicella-zoster virus antibodies)
Number of subjects: 20
Study 205687 — intervention group
Group type: COMPARATOR
Intervention: No transfusions
Number of subjects: 20
Study 30681196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal stimulation with a pleasant odor (odor condition) via an olfactometer or odorized nasal clip
Number of subjects: 40
Study 30681196 — intervention group
Group type: COMPARATOR
Intervention: Clean air (placebo condition) via an olfactometer
Number of subjects: 40
Study 28601733 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 1.2% simvastatin gel
Number of subjects: 46
Study 28601733 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 46
Study 26493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DEB (paclitaxel-coated drug-eluting balloon)
Number of subjects: 72
Study 26493253 — intervention group
Group type: COMPARATOR
Intervention: Passeo-18 PTA (uncoated balloon)
Number of subjects: 72
Study 23864403 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-informed intervention (Grady Nia Project)
Number of subjects: 89
Study 23864403 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 89
Study 21171837 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAC programme (outreach, problem solving, adherence, continuity)
Number of subjects: 133
Study 21171837 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 133
Study 19365151 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (10 mg)
Number of subjects: 16
Study 19365151 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (20 mg)
Number of subjects: 16
Study 19365151 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16
Study 19365151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17606461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic 22G needle
Number of subjects: 27
Study 17606461 — intervention group
Group type: COMPARATOR
Intervention: Traumatic needle (TN)
Number of subjects: 27
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: High producer genotypes for IL-6 (G/G and G/C) and TNF-alpha (G/A and A/A)
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: High and intermediate producer genotypes for IL-10 (G/G and G/A)
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer genotype (G/A and A/A)
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 high producer genotypes
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer genotype
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 high/intermediate producer genotype
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine genotype combinations (TNF-alpha high producer and IL-6 high producer; IL-6 high producer and IL-10 low producer)
Number of subjects: 183
Study 15086488 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha high producer and IL-10 low producer genotype combination
Number of subjects: 183
Study 11747684 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day or 10 mg/day)
Number of subjects: 670
Study 11747684 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 120 mg/day)
Number of subjects: 670
Study 11747684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hormone replacement therapy (HRT)
Number of subjects: 670
Study 11747684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 11747684 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, Raloxifene, or Combination HRT
Number of subjects: 670
Study 9676945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m HMPAO labeled leukocyte scintigraphy
Number of subjects: 23
Study 9676945 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m nanocolloid scintigraphy
Number of subjects: 23
Study 7826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg single dose) before amiodarone therapy
Number of subjects: 0
Study 7826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg single dose) after one month of amiodarone therapy (400 mg daily)
Number of subjects: 0
Study 7826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg daily for one month)
Number of subjects: 0
Study 3292345 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 97
Study 3292345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 29574365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (days 0, 14, 28, then every 28 days)
Number of subjects: 462
Study 29574365 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg (daily)
Number of subjects: 462
Study 28242871 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04958242
Number of subjects: 29
Study 28242871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 26307942 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted behavioral treatment for CUD with tobacco intervention and nicotine-replacement therapy (NRT)
Number of subjects: 32
Study 26307942 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (treatment for CUD but not tobacco)
Number of subjects: 32
Study 23142295 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 102
Study 23142295 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture (MF)
Number of subjects: 102
Study 23142295 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement (D)
Number of subjects: 102
Study 23142295 — intervention group
Group type: COMPARATOR
Intervention: Intact articular cartilage (IAC)
Number of subjects: 102
Study 23142295 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (OAT, MF, D, IAC)
Number of subjects: 102
Study 22017924 — intervention group
Group type: EXPERIMENTAL
Intervention: VoorZorg (Nurse Family Partnership adapted for the Netherlands)
Number of subjects: 0
Study 22017924 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 19157297 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (ATS)
Number of subjects: 31
Study 19157297 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (QN)
Number of subjects: 31
Study 19157297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16862038 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-directed personal care services (PCS)
Number of subjects: 2008
Study 16862038 — intervention group
Group type: COMPARATOR
Intervention: Traditional Medicaid PCS
Number of subjects: 2008
Study 16862038 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-directed PCS
Number of subjects: 2008
Study 16862038 — intervention group
Group type: COMPARATOR
Intervention: New PCS applicants
Number of subjects: 2008
Study 14616157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy
Number of subjects: 36
Study 10695692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium, 5 mg/d (increased to 10 mg/d after 2 years)
Number of subjects: 6459
Study 10695692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6459
Study 9586534 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free), chewed for 20 minutes five times each day after toothbrushing and Peridex rinse
Number of subjects: 150
Study 9586534 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (control group)
Number of subjects: 150
Study 9586534 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free)
Number of subjects: 150
Study 8267492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 61
Study 8267492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 61
Study 8267492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 61
Study 2685479 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care intervention
Number of subjects: 13
Study 2685479 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (as a subgroup of home care)
Number of subjects: 13
Study 786310 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam therapy at a dosage of 3 X 1600 mg per day
Number of subjects: 78
Study 786310 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam therapy at a dosage of 3 X 800 mg per day
Number of subjects: 78
Study 786310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 31145350 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming system set at 42°C (group F2)
Number of subjects: 243
Study 31145350 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming system set at 38°C (group F1)
Number of subjects: 243
Study 31145350 — intervention group
Group type: COMPARATOR
Intervention: Regular blanket (group C)
Number of subjects: 243
Study 29034009 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine as epigenetic priming induction (Arm A)
Number of subjects: 24
Study 29034009 — intervention group
Group type: COMPARATOR
Intervention: Standard induction (Arm B)
Number of subjects: 24
Study 25220709 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG/EE contraceptive patch
Number of subjects: 2160
Study 25220709 — intervention group
Group type: COMPARATOR
Intervention: Combination oral contraceptive 20 (LNG 100 μg per EE 20 μg)
Number of subjects: 2160
Study 25220709 — intervention group
Group type: COMPARATOR
Intervention: Combination oral contraceptive 30 (LNG 150 μg per EE 30 μg)
Number of subjects: 2160
Study 23769143 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol candy drops
Number of subjects: 99
Study 23769143 — intervention group
Group type: COMPARATOR
Intervention: PEG‐E
Number of subjects: 99
Study 20934757 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day oral essential amino acids (EAAs)
Number of subjects: 80
Study 20934757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20934757 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA supplementation
Number of subjects: 80
Study 20934757 — intervention group
Group type: EXPERIMENTAL
Intervention: WIG (without-infection group)
Number of subjects: 80
Study 17901913 — intervention group
Group type: EXPERIMENTAL
Intervention: Early computed tomography (CT) within one hour of admission
Number of subjects: 99
Study 16460374 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, structured, 3-month physical exercise program
Number of subjects: 100
Study 16460374 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 15504997 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide twice daily
Number of subjects: 377
Study 15504997 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide twice daily
Number of subjects: 377
Study 15504997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 11787912 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying own medical records
Number of subjects: 21
Study 8950733 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid insulin concentration (AFI) based treatment
Number of subjects: 123
Study 8950733 — intervention group
Group type: COMPARATOR
Intervention: Mean maternal blood glucose values (MBG) based treatment
Number of subjects: 123
Study 1904845 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Van (SV) with full economic incentive
Number of subjects: 90
Study 1904845 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic Motivator (AM) with full economic incentive
Number of subjects: 90
Study 1904845 — intervention group
Group type: COMPARATOR
Intervention: Basic Eye Health Worker (BW)
Number of subjects: 90
Study 1904845 — intervention group
Group type: COMPARATOR
Intervention: Mass Media (MM)
Number of subjects: 90
Study 1904845 — intervention group
Group type: COMPARATOR
Intervention: Partial economic incentive interventions
Number of subjects: 90
Study 1904845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 7138234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride and naltrexone hydrochloride combination treatment
Number of subjects: 11
Study 7138234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 11
Study 7138234 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride
Number of subjects: 11
Study 7138234 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms (anxiety, restlessness, muscular aching)
Number of subjects: 11
Study 31584030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing CPP-ACP
Number of subjects: 60
Study 31584030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing xylitol
Number of subjects: 60
Study 31584030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish with 0.9% difluorosilane
Number of subjects: 60
Study 31584030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish with prior oral prophylaxis
Number of subjects: 60
Study 31584030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish without prior oral prophylaxis
Number of subjects: 60
Study 28656910 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine 10 mg
Number of subjects: 120
Study 28656910 — intervention group
Group type: COMPARATOR
Intervention: levocetirizine 5 mg + montelukast 10 mg
Number of subjects: 120
Study 25872649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX)
Number of subjects: 160
Study 25872649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23879226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Elder Life Program (HELP)
Number of subjects: 0
Study 21460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum penetrating acupuncture
Number of subjects: 10
Study 21460396 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham needles
Number of subjects: 10
Study 19588534 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) treatment, 4 treatments at 2-week intervals, 15 J/cm2 energy, 3 ms pulse length, no cooling, 7 mm spot size with 10% overlap
Number of subjects: 20
Study 19588534 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) treatment
Number of subjects: 20
Study 17521782 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent A/C/W135 polysaccharide vaccine
Number of subjects: 360
Study 17521782 — intervention group
Group type: COMPARATOR
Intervention: Tetravalent A/C/Y/W135 polysaccharide vaccine
Number of subjects: 360
Study 17521782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 360
Study 15334027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 87
Study 15334027 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 87
Study 11114571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration with cellulose dialyzers
Number of subjects: 11
Study 11114571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration with synthetic dialyzers
Number of subjects: 11
Study 9586609 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser resection of the prostate (HoLRP)
Number of subjects: 44
Study 9586609 — intervention group
Group type: COMPARATOR
Intervention: Neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate (VLAP)
Number of subjects: 44
Study 8083794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-brushing rinse (PBR)
Number of subjects: 4
Study 8083794 — intervention group
Group type: COMPARATOR
Intervention: Plain tap water
Number of subjects: 4
Study 8083794 — intervention group
Group type: COMPARATOR
Intervention: Brushed only
Number of subjects: 4
Study 8083794 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 4
Study 2636654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoacid mixture (KAM) containing 10.9% (R,S) alpha-keto-beta-methylvalerate, meal dose of 6.2 +/- 0.25 g or 9.3 +/- 0.55 g
Number of subjects: 0
Study 606773 — intervention group
Group type: EXPERIMENTAL
Intervention: A/Shope vaccine (200 CCA units/dose)
Number of subjects: 0
Study 606773 — intervention group
Group type: EXPERIMENTAL
Intervention: A/X-53 vaccine (200 CCA units/dose)
Number of subjects: 0
Study 31162829 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 142
Study 31162829 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 142
Study 29202204 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (8-week program)
Number of subjects: 151
Study 29202204 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 151
Study 26442395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Stimulator‐Guided Group (NSG)
Number of subjects: 36
Study 26442395 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guided group (USG)
Number of subjects: 36
Study 23370663 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg/kg A(1-7)
Number of subjects: 34
Study 23370663 — intervention group
Group type: COMPARATOR
Intervention: 300 mcg/kg A(1-7)
Number of subjects: 34
Study 20621509 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 0
Study 20621509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 19437312 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg single dose of azithromycin
Number of subjects: 99
Study 19437312 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/kg single dose of azithromycin
Number of subjects: 99
Study 17294232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 26
Study 17294232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15548447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 128
Study 15548447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 128
Study 11380220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paste containing antibiotics polymyxin E, tobramycin, and amphotericin B (PTA group)
Number of subjects: 77
Study 11380220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9239626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing biofeedback training device (experimental group)
Number of subjects: 60
Study 9239626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 8505745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama (yogic breathing and stretch)
Number of subjects: 71
Study 8505745 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 71
Study 8505745 — intervention group
Group type: COMPARATOR
Intervention: Visualization
Number of subjects: 71
Study 3086019 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium washout technique (wVD/VT)
Number of subjects: 55
Study 3086019 — intervention group
Group type: COMPARATOR
Intervention: Conventional Bohr's method (VD/VT)
Number of subjects: 55
Study 3086019 — intervention group
Group type: COMPARATOR
Intervention: Rebreathing technique (AVD/VT)
Number of subjects: 55
Study 29504780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (0.4 mg/g to 15.8 mg/g nicotine)
Number of subjects: 839
Study 29504780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (0.4 mg/g)
Number of subjects: 839
Study 29504780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) conditions
Number of subjects: 839
Study 29504780 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content (NNC) cigarettes
Number of subjects: 839
Study 27475338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin B6 (60 mg of intravenous pyridoxal 5'-phosphate after each thrice-weekly hemodialysis session)
Number of subjects: 56
Study 27475338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 24356792 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 357
Study 24356792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 21707472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 59
Study 21707472 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 59
Study 19276646 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 306
Study 19276646 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 306
Study 17591468 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.9-mm-diameter one-plane bending high resolution videoendoscope
Number of subjects: 122
Study 17591468 — intervention group
Group type: COMPARATOR
Intervention: 5.9-mm-diameter standard videoendoscope
Number of subjects: 122
Study 15370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathy treatment
Number of subjects: 48
Study 15370183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (continued)
Number of subjects: 48
Study 15370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (switched to placebo)
Number of subjects: 48
Study 15370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall subjects
Number of subjects: 48
Study 11591835 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg/kg IV over 24 hours)
Number of subjects: 190
Study 11591835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 11591835 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole in TACS subgroup
Number of subjects: 190